Sabicard 100 - Tablet Sacubitril + Valsartan - 49mg+51mg 10 Tablet(s) / Box Aristopharma Limited Introduction: Sabicard 100 is a combination medicine used to treat heart failure. It reduces the risk of hospitalization and death due to long-lasting (chronic) heart failure. Sabicard 100 can be taken with or without food but is best taken at the same time(s) each day. Swallow it as a whole with water. Your dose, and how often you take it, will be decided by your doctor and may change depending on how well you respond to the medicine. Keep taking the tablets regularly, as they have been prescribed, and try not to miss doses to get the most benefit. Do not... Uses of Sabicard 100: Heart failure Side effects of Sabicard 100: CoughDizzinessOrthostatic hypotension (sudden lowering of blood pressure on standing)Altered levels of potassium in bloodDecreased red blood cell countDecreased blood pressureHypoglycemia (low blood glucose level)DiarrheaFaintingHeadacheNauseaStomach painVertigoWeakness How to use Sabicard 100: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Sabicard 100 may be taken with or without food, but it is better to take it at a fixed time. How Sabicard 100 works: Sabicard 100 is a combination of two medicines: Sacubitril and Valsartan which belong to a class of angiotensin receptor neprilysin inhibitor (ARNI). This combination treats heart failure by relaxing the blood vessels and making it easier for your heart to pump blood throughout your body. In addition, it also helps your body retain less water. Indication: Heart Failure, Administration: May take with or without food Adult Dose: Heart Failure Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure (HF) in patients with chronic heart failure (CHF) (NYHA class II-IV) and reduced ejection fraction Recommended starting dose: 49 mg/51 mg PO BID Target maintenance dose: After 2-4 weeks, double the dose to the target maintenance dose of 97 mg/103 mg PO BID as tolerated Hepatic impairment Mild (Child-Pugh A): No starting dose adjustment required Moderate (Child-Pugh B): Reduce starting dose to 24 mg/26 mg BID; double the dose every 2-4 weeks to target maintenance dose of 97 mg/103 mg BID as tolerated Severe (Child-Pugh... Renal Dose: Renal impairment Mild-to-moderate (eGFR ?30 mL/min/1.73 m²): No starting dose adjustment required Severe (eGFR <30 mL/min/1.73 m²): Reduce starting dose to 24 mg/26 mg BID; double the dose every 2-4 weeks to target maintenance dose of 97 mg/103 mg BID as tolerated Contraindication: Hypersensitivity to any component History of angioedema related to previous ACE inhibitor or ARB therapy Coadministration of neprilysin inhibitors (eg, sacubitril) with ACE inhibitors may increase angioedema risk; do not administer ACE inhibitors within 36 hr of switching to or from sacubitril/valsartan Concomitant use with aliskiren in patients with diabetes Mode of Action: Combination is an angiotensin receptor-neprilysin inhibitor (ARNi) Sacubitril: Neprilysin inhibitor; neprilysin is responsible for degradation of atrial and brain natriuretic peptide; the cardiovascular and renal effects of sacubitril’s active metabolite (LBQ657) in heart failure are attributed to the increased levels of peptides that are degraded by neprilysin (eg, natriuretic peptide); administration results in increased natriuresis, increased urine cGMP, and decreased plasma MR-proANP and NT-proBNP Valsartan: Angiotensin II receptor type I inhibitor; decreases blood pressure and blocks vasoconstrictor and aldosterone-secreting effects of angiotensin II Precaution: Can cause fetal harm when administered to a pregnant woman; use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death (see Black Box Warnings) Observe for signs and symptoms of angioedema; if angioedema occurs, discontinue drug immediately, provide appropriate therapy, and monitor for airway compromise Sacubitril/valsartan lowers blood pressure and may cause symptomatic hypotension; patients who are volume-depleted or salt-depleted, or those taking diuretics, are at greater risk Monitor renal function and potassium levels in susceptible patients (eg, diabetes, hypoaldosteronism, high-potassium... Side Effect: >10% Hypotension (18%) Hyperkalemia (12%) 1-10% Cough (9%) Dizziness (6%) Orthostasis (2.1%) Falls (1.9%) <1% Angioedema, all patients (0.5%); in black patients (2.4%)